REFLAB ApS: Financial statements 2012
CVR: 15322586
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
REFLAB ApS (CVR 15322586) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK 2,528,583 and a net result of DKK -64,717. Equity in the 2012 report amounted to DKK 2,682,799. The solvency ratio was 75.7%.
- Gross Profit
- DKK 2,528,583
- Profit/Loss
- DKK -64,717
- Equity
- DKK 2,682,799
- Total Assets
- DKK 3,542,756
Official annual report
Keep an eye on REFLAB ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of December 14, 2012, Erik Dahl Jensen is registered as director of REFLAB ApS.
As of December 14, 2012, Per Stahl Skov has stepped down as director of REFLAB ApS.
As of December 14, 2012, Eva Valbjørn Sørensen has stepped down as director of REFLAB ApS.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 7 employees (2018). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.